Acinetobacter baumannii Ventilator-Associated Pneumonia: Clinical Efficacy of Combined Antimicrobial Therapy and in vitro Drug Sensitivity Test Results
Objective: To evaluate therapeutic efficacy of different combined antimicrobial treatments against Acinetobacter baumannii ventilator-associated pneumonia (VAP).Methods: Clinical outcomes were retrospectively analyzed to elucidate the efficacy of four combined antimicrobial regimens. The chessboard...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2019-02-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2019.00092/full |
| _version_ | 1811219359374245888 |
|---|---|
| author | Yuqin Huang Quan Zhou Quan Zhou Wenguo Wang Qiang Huang Juan Liao Junyi Li Lei Long Tao Ju Quan Zhang Hanqin Wang Huaqiang Xu Mingli Tu Mingli Tu |
| author_facet | Yuqin Huang Quan Zhou Quan Zhou Wenguo Wang Qiang Huang Juan Liao Junyi Li Lei Long Tao Ju Quan Zhang Hanqin Wang Huaqiang Xu Mingli Tu Mingli Tu |
| author_sort | Yuqin Huang |
| collection | DOAJ |
| description | Objective: To evaluate therapeutic efficacy of different combined antimicrobial treatments against Acinetobacter baumannii ventilator-associated pneumonia (VAP).Methods: Clinical outcomes were retrospectively analyzed to elucidate the efficacy of four combined antimicrobial regimens. The chessboard and micro broth dilution methods determined the minimum inhibitory concentrations (MICs) of four antiseptic drugs singly used and combined two drugs against 36 isolates of multidrug-resistant (MDR) A. baumannii.Results: The incidence of VAP was approximately 6.9% (237/3424) between January 1, 2015 and December 31, and 35.9% (85/237) of the cases were caused by A. baumannii. Among these cases, 60 belonged to AB-VAP, for whom antimicrobial treatment plan was centralized and clinical data was complete. Moreover, all 60 strains of A. baumannii were MDR bacteria from reports microbiological laboratory. Resistance rate was lowest for amikacin (68.3%) and ampicillin sulbactam (71.7%). Resistance rate for imipenem increased from 63.2 to 90.9% during the 3 years. However, in these 60 cases of AB-VAP, the combination between 4 antibiotics was effective in most cases: the effective rate was 75% (18/24) for sulbactam combined with etilmicin, 71.4% (10/14) for sulbactam combined with levofloxacin, 72.7% (8/11) for meropenem combined with etilmicin, and 63.6% (7/11) for meropenem combined with levofloxacin. There was no statistical difference between four regimens (P > 0.05). Sulbactam combined with etilmicin decreased 1/2 of MIC50 and MIC90 of sulbactam while the decreases in etilmicin were more obviously than single drug. When adopting meropenem combined with levofloxacin or etilmicin, the MIC of meropenem reduced to 1/2 of that in applying single drug. As for sulbactam or meropenem combined with levofloxacin, it also lessened the MIC50 of levofloxacin to 1/2 of that for single drug. FIC results suggested that the effects of four combined antimicrobial regimens were additive or unrelated. When sulbactam was combined with etimicin, the additive effect was 63.89%.Conclusion: Drug combination sensitivity test in vitro may be helpful for choosing antimicrobial treatment plans. Sulbactam or meropenem as the basis of treatment regimens can function as the alternatives against AB-VAP. Sulbactam combined with etimicin has been regarded as a recommended regimen in Suizhou, Hubei, China. |
| first_indexed | 2024-04-12T07:25:57Z |
| format | Article |
| id | doaj.art-4e8118db5a004b75af04d409c562ea3e |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-12T07:25:57Z |
| publishDate | 2019-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-4e8118db5a004b75af04d409c562ea3e2022-12-22T03:42:12ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122019-02-011010.3389/fphar.2019.00092433804Acinetobacter baumannii Ventilator-Associated Pneumonia: Clinical Efficacy of Combined Antimicrobial Therapy and in vitro Drug Sensitivity Test ResultsYuqin Huang0Quan Zhou1Quan Zhou2Wenguo Wang3Qiang Huang4Juan Liao5Junyi Li6Lei Long7Tao Ju8Quan Zhang9Hanqin Wang10Huaqiang Xu11Mingli Tu12Mingli Tu13Intensive Care Unit, Suizhou Central Hospital, Hubei University of Medicine, Suizhou, ChinaIntensive Care Unit, Suizhou Central Hospital, Hubei University of Medicine, Suizhou, ChinaSuixian People’s Hospital, Suizhou, ChinaIntensive Care Unit, Suizhou Central Hospital, Hubei University of Medicine, Suizhou, ChinaIntensive Care Unit, Suizhou Central Hospital, Hubei University of Medicine, Suizhou, ChinaIntensive Care Unit, Suizhou Central Hospital, Hubei University of Medicine, Suizhou, ChinaDepartment of Gastroenterology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaIntensive Care Unit, Suizhou Central Hospital, Hubei University of Medicine, Suizhou, ChinaIntensive Care Unit, Suizhou Central Hospital, Hubei University of Medicine, Suizhou, ChinaIntensive Care Unit, Suizhou Central Hospital, Hubei University of Medicine, Suizhou, ChinaCenter for Translational Medicine, Suizhou Central Hospital, Hubei University of Medicine, Suizhou, ChinaIntensive Care Unit, Suizhou Central Hospital, Hubei University of Medicine, Suizhou, ChinaSuixian People’s Hospital, Suizhou, ChinaDepartment of Respiratory Medicine, Suizhou Central Hospital, Hubei University of Medicine, Suizhou, ChinaObjective: To evaluate therapeutic efficacy of different combined antimicrobial treatments against Acinetobacter baumannii ventilator-associated pneumonia (VAP).Methods: Clinical outcomes were retrospectively analyzed to elucidate the efficacy of four combined antimicrobial regimens. The chessboard and micro broth dilution methods determined the minimum inhibitory concentrations (MICs) of four antiseptic drugs singly used and combined two drugs against 36 isolates of multidrug-resistant (MDR) A. baumannii.Results: The incidence of VAP was approximately 6.9% (237/3424) between January 1, 2015 and December 31, and 35.9% (85/237) of the cases were caused by A. baumannii. Among these cases, 60 belonged to AB-VAP, for whom antimicrobial treatment plan was centralized and clinical data was complete. Moreover, all 60 strains of A. baumannii were MDR bacteria from reports microbiological laboratory. Resistance rate was lowest for amikacin (68.3%) and ampicillin sulbactam (71.7%). Resistance rate for imipenem increased from 63.2 to 90.9% during the 3 years. However, in these 60 cases of AB-VAP, the combination between 4 antibiotics was effective in most cases: the effective rate was 75% (18/24) for sulbactam combined with etilmicin, 71.4% (10/14) for sulbactam combined with levofloxacin, 72.7% (8/11) for meropenem combined with etilmicin, and 63.6% (7/11) for meropenem combined with levofloxacin. There was no statistical difference between four regimens (P > 0.05). Sulbactam combined with etilmicin decreased 1/2 of MIC50 and MIC90 of sulbactam while the decreases in etilmicin were more obviously than single drug. When adopting meropenem combined with levofloxacin or etilmicin, the MIC of meropenem reduced to 1/2 of that in applying single drug. As for sulbactam or meropenem combined with levofloxacin, it also lessened the MIC50 of levofloxacin to 1/2 of that for single drug. FIC results suggested that the effects of four combined antimicrobial regimens were additive or unrelated. When sulbactam was combined with etimicin, the additive effect was 63.89%.Conclusion: Drug combination sensitivity test in vitro may be helpful for choosing antimicrobial treatment plans. Sulbactam or meropenem as the basis of treatment regimens can function as the alternatives against AB-VAP. Sulbactam combined with etimicin has been regarded as a recommended regimen in Suizhou, Hubei, China.https://www.frontiersin.org/article/10.3389/fphar.2019.00092/fullventilator-associated pneumoniaAcinetobacter baumanniicombined antimicrobial therapyin vitro drug sensitivity testmultidrug-resistant |
| spellingShingle | Yuqin Huang Quan Zhou Quan Zhou Wenguo Wang Qiang Huang Juan Liao Junyi Li Lei Long Tao Ju Quan Zhang Hanqin Wang Huaqiang Xu Mingli Tu Mingli Tu Acinetobacter baumannii Ventilator-Associated Pneumonia: Clinical Efficacy of Combined Antimicrobial Therapy and in vitro Drug Sensitivity Test Results Frontiers in Pharmacology ventilator-associated pneumonia Acinetobacter baumannii combined antimicrobial therapy in vitro drug sensitivity test multidrug-resistant |
| title | Acinetobacter baumannii Ventilator-Associated Pneumonia: Clinical Efficacy of Combined Antimicrobial Therapy and in vitro Drug Sensitivity Test Results |
| title_full | Acinetobacter baumannii Ventilator-Associated Pneumonia: Clinical Efficacy of Combined Antimicrobial Therapy and in vitro Drug Sensitivity Test Results |
| title_fullStr | Acinetobacter baumannii Ventilator-Associated Pneumonia: Clinical Efficacy of Combined Antimicrobial Therapy and in vitro Drug Sensitivity Test Results |
| title_full_unstemmed | Acinetobacter baumannii Ventilator-Associated Pneumonia: Clinical Efficacy of Combined Antimicrobial Therapy and in vitro Drug Sensitivity Test Results |
| title_short | Acinetobacter baumannii Ventilator-Associated Pneumonia: Clinical Efficacy of Combined Antimicrobial Therapy and in vitro Drug Sensitivity Test Results |
| title_sort | acinetobacter baumannii ventilator associated pneumonia clinical efficacy of combined antimicrobial therapy and in vitro drug sensitivity test results |
| topic | ventilator-associated pneumonia Acinetobacter baumannii combined antimicrobial therapy in vitro drug sensitivity test multidrug-resistant |
| url | https://www.frontiersin.org/article/10.3389/fphar.2019.00092/full |
| work_keys_str_mv | AT yuqinhuang acinetobacterbaumanniiventilatorassociatedpneumoniaclinicalefficacyofcombinedantimicrobialtherapyandinvitrodrugsensitivitytestresults AT quanzhou acinetobacterbaumanniiventilatorassociatedpneumoniaclinicalefficacyofcombinedantimicrobialtherapyandinvitrodrugsensitivitytestresults AT quanzhou acinetobacterbaumanniiventilatorassociatedpneumoniaclinicalefficacyofcombinedantimicrobialtherapyandinvitrodrugsensitivitytestresults AT wenguowang acinetobacterbaumanniiventilatorassociatedpneumoniaclinicalefficacyofcombinedantimicrobialtherapyandinvitrodrugsensitivitytestresults AT qianghuang acinetobacterbaumanniiventilatorassociatedpneumoniaclinicalefficacyofcombinedantimicrobialtherapyandinvitrodrugsensitivitytestresults AT juanliao acinetobacterbaumanniiventilatorassociatedpneumoniaclinicalefficacyofcombinedantimicrobialtherapyandinvitrodrugsensitivitytestresults AT junyili acinetobacterbaumanniiventilatorassociatedpneumoniaclinicalefficacyofcombinedantimicrobialtherapyandinvitrodrugsensitivitytestresults AT leilong acinetobacterbaumanniiventilatorassociatedpneumoniaclinicalefficacyofcombinedantimicrobialtherapyandinvitrodrugsensitivitytestresults AT taoju acinetobacterbaumanniiventilatorassociatedpneumoniaclinicalefficacyofcombinedantimicrobialtherapyandinvitrodrugsensitivitytestresults AT quanzhang acinetobacterbaumanniiventilatorassociatedpneumoniaclinicalefficacyofcombinedantimicrobialtherapyandinvitrodrugsensitivitytestresults AT hanqinwang acinetobacterbaumanniiventilatorassociatedpneumoniaclinicalefficacyofcombinedantimicrobialtherapyandinvitrodrugsensitivitytestresults AT huaqiangxu acinetobacterbaumanniiventilatorassociatedpneumoniaclinicalefficacyofcombinedantimicrobialtherapyandinvitrodrugsensitivitytestresults AT minglitu acinetobacterbaumanniiventilatorassociatedpneumoniaclinicalefficacyofcombinedantimicrobialtherapyandinvitrodrugsensitivitytestresults AT minglitu acinetobacterbaumanniiventilatorassociatedpneumoniaclinicalefficacyofcombinedantimicrobialtherapyandinvitrodrugsensitivitytestresults |